Update on Advanced Gastric Cancer: Guidelines and Current and Emerging Targeted Therapies
This activity is supported by an educational grant from Eli Lilly.
Charles S. Fuchs, MD, MPH
Director of the Gastrointestinal Malignancy Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Faculty Reviewer
Jaffer A. Ajani, MD
Professor of Cancer Medicine
MD Anderson Cancer Center
The University of Texas
Houston, Texas
Editorial Support
Paige S. Davies, PhD
Katherine DeYoung, PhD
Hitt Medical Writing, LLC
This activity is supported by an educational grant from Eli Lilly.
Activity Overview
This activity is designed to educate oncologists, surgical oncologists, gastroenterologists, pathologists, and oncology nurses on the optimal management of advanced gastric cancer.
It includes background on gastric cancer and information on the underlying signaling pathways in advanced gastric cancer, including human epidermal growth factor receptors, vascular endothelial growth factor receptors, and the MET hepatocyte growth factor receptor. This CME activity also includes the most recent clinical practice guidelines for management of gastric cancer as well as information on HER2 status and trastuzumab clinical trial data. This CME includes late-stage clinical trial data on emerging targeted therapies for the treatment of advanced gastric cancer, including ramucirumab, apatinib, neratinib, lapatinib, trastuzumab emtansine (T-DM1), pertuzumab, rilotumumab, and onartuzumab. Lastly, this CME introduces readers to immune-based therapies in gastric cancer.
Educational Objectives
- Summarize aberrant signaling pathways in advanced gastric cancer
- Develop treatment regimens for patients with gastric cancer based on recently updated guidelines
- Analyze recent clinical trial data on emerging targeted therapies for the treatment of advanced gastric cancer
Upon completion of this educational activity, participants should be able to:Target Audience:Oncologists, surgical oncologists, gastroenterologists, pathologists, and oncology nurses
Type of Activity:Knowledge
Release date:August 30, 2014
Expiration date:August 30, 2015
Estimated time to complete activity:2 hours
To continue, click here > >
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
